Omada Health, Inc. Common Stock logo

Omada Health, Inc. Common Stock(OMDA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$14.33
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for OMDA

11/13/2026: OMDA (1-star) is currently NOT-A-BUY. Pass it for now.

Omada Health is a publicly traded digital health company that provides virtual-first chronic care management for cardiometabolic and musculoskeletal conditions. The company's strengths include a strong, evidence-based clinical platform and strategic hardware partnerships, which have fueled significant customer adoption among large enterprises. Its primary growth opportunity lies in its ability to support members managing GLP-1 weight-loss medications through remote coaching. However, investors must weigh these strengths against risks such as intense competition from major telehealth players, dependency on contract renewals, and execution risks following recent executive leadership changes. The stock may suit growth-oriented investors who are comfortable with the inherent volatility of the early-stage digital health market.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company operates in a high-growth sector with proven revenue momentum and a scalable digital platform.
Momentum investorMixed fitMomentum investors should monitor for sustained positive price action and volume signals.
Value investorWeak fitThe company is a growth-stage entity and current valuations reflect future potential rather than traditional value metrics.
Dividend investorWeak fitOmada does not pay a dividend and is focused on reinvesting cash flow into market expansion.
Low-risk investorWeak fitHigh volatility and the risks associated with the early-stage public market performance make this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock has displayed significant intraday and long-term price fluctuations typical of growth-stage healthcare IPOs.
Valuation riskMedium / highAs a growth company, the stock's valuation is highly dependent on achieving future revenue growth targets.
Competition risk (Digital Health incumbents)HighIntense pressure from larger, established telehealth players threatens to compress margins and market share.
Business qualityMediumWhile the clinical platform is robust, the company is still building a consistent track record of profitability.
Dividend incomeLow / noneThe company does not provide income through dividends.
Execution riskMedium / highSuccessfully managing the transition to a new CEO and scaling operations to meet client demand is critical for future performance.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 889.00M USD
Price to earnings Ratio 35.83
1Y Target Price 26.92
Price to earnings Ratio 35.83
1Y Target Price 26.92
Volume (30-day avg) 1.2M shares
Beta -
52 Weeks Range 10.28 - 25.45
Updated Date 11/14/2026
52 Weeks Range 10.28 - 25.45
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.4

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Health Information Services

BUY participation
100.0%
Active BUY / eligible
4 / 4
30-Day BUY Count Change
+2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 23.25%
Avg. Invested days 43
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
OMDA receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
OMDA has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+72.9%) and solid cash generation (FCF margin 6.5%) are partially offset by weak profitability (net margin -4.9%), modest insider ownership of 2.12%.

Financial Health Rating

★★★★★
OMDA's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 64.6%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is OMDA's strongest growth driver at +144.5% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+53.2%, strong) and earnings growth (+72.9%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 87.2% and approximately 83.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.12% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Revelation Capital Management, LLC 7.94%
Divisadero Street Capital Management, LP 6.21%
American Century Companies Inc 6.01%
Cigna Investments Inc 5.63%
Morgan Stanley - Brokerage Accounts 4.58%

Unit Economics (Per $1K Revenue)

★★★★★
OMDA generates approximately $657 of gross profit, $-46 of operating income, and $65 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
OMDA has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Chronic Care ServicesSubscription-based contracts with health plans, employers, and health systems for digital chronic disease management.Revenue is primarily driven by recurring service fees paid by large organizations to help their members stay healthy.
Connected Device IntegrationIncorporation of monitoring device costs (e.g., blood pressure cuffs, scales, CGMs) into service contracts.The company earns revenue by acting as a provider of both the digital software and the physical monitoring tools.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When After Market
Estimate 0.02
Actual 0.1

Profitability

Profit Margin 4.21%
Operating Margin (TTM) 2.06%

Management Effectiveness

Return on Assets (TTM) 1.35%
Return on Equity (TTM) 5.72%

Valuation

Trailing PE 35.83
Forward PE 44.64
Enterprise Value 718.77M
Price to Sales(TTM) 2.67
Enterprise Value 718.77M
Price to Sales(TTM) 2.67
Enterprise Value to Revenue 2.16
Enterprise Value to EBITDA 34.96
Shares Outstanding 62.04M
Shares Floating 51.85M
Shares Outstanding 62.04M
Shares Floating 51.85M
Percent Insiders 2.12
Percent Institutions 87.21

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.